Parkinson's disease therapy developer Aspen Neuroscience (ASPE.US) IPO priced at $15-17 per share, aiming to raise $150 million.

Zhitong Finance APP has learned that Aspen Neuroscience, a clinical-stage biotech company developing a stem cell therapy for Parkinson's disease, announced the terms of its IPO on Monday. The San Diego, California-based company plans to offer 9.4 million shares at a price of $15 to $17 per share to raise $150 million. Based on the midpoint of the proposed offering range, Aspen Neuroscience's fully diluted market value is approximately $494 million.